We report here a 58-year-old patient with clonal FIP1L1-PDGFRA-positive hypereosinophilic syndrome (HES), with skin and lung involvement, treated with Imatinib, in clinical, hematological and molecular remission. After 77 months of treatment, Imatinib was stopped and at 9 months of discontinuation, the patient remained in complete molecular remission.